基于个体发育癌场理论的外阴癌手术治疗:单中心前瞻性试验
该单中心前瞻性试验纳入97例外阴癌患者,按个体发育癌场理论行外阴癌场切除术、腹股沟盆腔淋巴结清扫及解剖重建,不辅以放疗。结果支持个体发育癌场理论,需多中心随机试验进一步验证。
要点
- 外阴癌场切除术基于个体发育癌场理论,可指导局部和区域治疗。
- 术后中重度并发症常见,多为感染性伤口裂开。
核心结论
- 结果支持外阴癌个体发育癌场理论,与宫颈癌发现一致,提示理论通用性。
- 癌场切除术概念可能改善外阴癌结局,但需多中心随机对照试验验证。
研究设计与样本
- 单中心、单组、前瞻性试验,在莱比锡大学癌症中心进行。
- 纳入97例18岁以上、个体发育分期1-3b、组织学证实的原发性外阴癌患者,既往未接受手术或放疗。
- 根据个体发育分期行部分、全或扩大外阴癌场切除术,治疗性腹股沟盆腔淋巴结清扫,解剖重建,不辅以放疗。
- 主要终点为无复发生存率、疾病特异性生存率和早期术后并发症。
主要发现
- 97例患者纳入,94例按方案治疗。
- 46例(按意向治疗分析)发生中重度术后并发症,尤其是感染性会阴和腹股沟伤口裂开。
临床怎么用
- 基于个体发育癌场理论的外阴癌场切除术可作为外阴癌手术治疗的一种选择。
- 需注意术后感染性伤口裂开等中重度并发症的防治。
局限性
- 单中心、单组、前瞻性试验,非随机对照,证据级别有限。
- 样本量97例,需多中心随机对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of vulvar cancer is increasing, but surgical treatment-the current standard of care-often leads to unsatisfactory outcomes, especially in patients with node-positive disease. Preliminary results at our centre showed that locoregional spread of vulvar carcinoma occurs within tissue domains defined by stepwise embryonic and fetal development (ontogenetic cancer fields and associated lymph node regions). We propose that clinical translation of these insights into practice could improve outcomes of surgical treatment of vulvar cancer. METHODS: We did a single-centre prospective trial at the University of Leipzig's Cancer Center. Eligible patients were aged 18 years or older, had ontogenetic stage 1-3b histologically proven primary carcinoma of the vulva, and had not undergone previous surgical or radiotherapy treatment for vulvar cancer or any other major perineal or pelvic disease. In view of staged morphogenesis of the vulva from the cloacal membrane endoderm at Carnegie stage 11 to adulthood, we defined the tissue domains of tumour spread according to the theory of ontogenetic cancer fields. On the basis of ontogenetic staging, patients were treated locally with partial, total, or extended vulvar field resection; regionally with therapeutic inguinopelvic lymph node dissection; and anatomical reconstruction without adjuvant radiotherapy. The primary endpoints were recurrence-free survival, disease-specific survival, and early postoperative complications. Analysis of tumour spread and early postoperative surgical complications was done by intention to treat (ie, all patients were included), whereas outcome analyses were done per protocol. This ongoing trial is registered with the German Clinical Trials Register, number DRKS00013358. FINDINGS: Between March 1, 2009, and June 8, 2017, 97 consecutive patients were included in the study, of whom 94 were treated per protocol with vulvar field resection, therapeutic inguinopelvic lymph node dissection, and anatomical reconstruction without adjuvant radiotherapy. 46 patients had moderate or severe postoperative complications, especially infectious perineal and inguinal wound dehiscence. 3-year recurrence-free survival in all patients was 85·1% (95% CI 76·9-93·3), and 3-year disease-specific survival was 86·0% (78·2-93·8). INTERPRETATION: Our results support the theory of ontogenetic cancer fields for vulvar carcinoma, accord with our previous findings in cervical cancer, and suggest the general applicability of the theory. Application of the concept of cancer field resection could improve outcomes in patients with vulvar carcinoma, but needs to be investigated further in multicentre randomised controlled trials. FUNDING: Leipzig School of Radical Pelvic Surgery and Gynecologic Oncology Research Foundation.
引用
- Höckel M, Trott S, Dornhöfer N, et al. Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial. Lancet Oncol. 2018. PMID: 29530664. doi:10.1016/S1470-2045(18)30109-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。